The hub genes in the highest-scoring subnetwork, which we considered essential therapeutic targets for BZYQ in treating DN, included NLRP3, ASC, caspase-1, GSDMD, IL-1β, and IL-18 (Fig. 3b). The gene discussed is GSDMD; the disease is liver dysplastic nodule.